This activity will provide comprehensive and up-to-date information regarding the most recent and relevant laws and clinical practice guidelines regarding the safe and effective management and treatment of pain, including opioid and other substance use disorders. The 8-course series will yield practical guidance for prescribing clinicians who manage patients with pain and/or substance use disorders, including detailed information on appropriate treatment selection and management, risk mitigation strategies, and implementation of diversion and surveillance tools for controlled substances. Completion of this activity in full will satisfy the Drug Enforcement Administration (DEA) 8-hour content training requirement for The Medication Access and Training Expansion (MATE) Act.

Target Audience

This activity is designed for All Drug Enforcement Administration (DEA)-registered practitioners who treat patients with opioid or other substance use disorders, including: physicians, nurse practitioners, physician assistants, and dentists.

Learning Objectives

Upon completion of the educational activity, participants will be able to:

· Distinguish appropriate actions for prescribers and dispensers related to the federal laws regarding prescription practices for controlled substances via in person and by way of telemedicine settings.

· Explain the appropriate use for and application of opioids and non-opioids in clinical practice, including initiation, continuation/discontinuation, forced opioid tapers, and dose escalation.

· Identify appropriate areas of clinical assessment and evaluation of treatment failure, including how to adequately analyze risks and benefits of specific dosing regimens.

· Integrate workflows that foster responsible opioid prescribing practices, incorporate appropriate risk mitigation strategies and improve the informed consent process between clinicians and patients.

· Outline best practices regarding the implementation of tools for diversion and surveillance of controlled substances.

Course summary
Available credit: 
  • 8.25 AANP
  • 8.25 AAPA Category I CME
  • 8.25 ACCME (All Other)
  • 8.25 ACCME (MD/DO Only)
Course opens: 
Course expires: 

Charles E. Argoff MD

Professor of Neurology

Director of Comprehensive Pain Program

Albany Medical Center

Albany, NY

Timothy J. Atkinson PharmD

National Program Manager, Pain/Opioid Pharmacy Program Specialist

VHA Pain Management, Opioid Safety, PDMP (PMOP)

Director, PGY2 Pain Management & Palliative Care Residency

Murfreesboro, TN

Jeffrey J. Bettinger PharmD

Pain Management Clinical Pharmacist

Saratoga Hospital Medical Group

Schenectady, NY

Jennifer Bolen JD


The J. Bolen Group, LLC

Lenoir City, TN

Michelle E. Brown PharmD, BCPS

Clinical Pharmacy Specialist - Pain and Opioid Stewardship

Eskenazi Health

Indianapolis, IN

Mark P. Garofoli PharmD, MBA, BCGP, CPE, CTTS

Clinical Assistant Professor & Clinical Pain Management Pharmacist

West Virginia University & West Virginia University Medicine

Morgantown, WV

Jessica E. Geiger PharmD, MS, BCPS

Clinical Pharmacy Practitioner

Palliative Care

VA Northern California

Powell, OH

Andrew C. Lodolo PharmD, BCPS, BCCCP, FCCM

Pharmacy Manager, Inpatient Services

Eskenazi Health

Indianapolis, IN

Friedhelm Sandbrink MD

National Executive Director

Pain Management, Opioid Safety, and PDMP

VHA Pain Management, Opioid Safety, PDMP (PMOP)

Murfreesboro, TN

Tanya J. Uritsky PharmD, BCPP

Opioid Stewardship Coordinator

Hospital of the University of Pennsylvania

Malvern, PA

Criteria for Success

To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. If you have questions about this activity, please contact AKH Inc. at

CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.


In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and PAINWeek. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 8.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistant

AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 8.25 AAPA Category 1 CME credits. Approval is valid until Expiration.  Approval is valid until September 29, 2024. PAs should only claim credit commensurate with the extent of their participation.


Nurse Practitioners

 This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and PAINWeek. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 8.25 contact hour(s) (which includes 8.25 hour(s) of pharmacology).

Commercial Support

There is no commercial support for this activity.




Commercial Interest

Charles E. Argoff, MD


Tris, Nevro, Vertex, Kowa, Lundbeck, Collegium, XGene Pharma, Amgen


Abbvie, Vertex, Lundbeck, Lilly

Speakers Bureau

Abbvie, Impel, Biohaven, Lilly, Lundbeck


Stock Shareholder


Timothy J. Atkinson, PharmD


Nothing to disclose

Jeffrey J. Bettinger, PharmD



Hisamitsu America, Inc., PainScript, LLC.

Jennifer Bolen, JD


Paradigm Labs for Compliance Consulting


Forte Biopharma

Michelle E. Brown, PharmD, BCPS


Nothing to disclose

Mark P. Garofoli, PharmD, MBA, BCGP, CPE, CTTS


Nothing to disclose

Jessica E. Geiger, PharmD, MS, BCPS


Nothing to disclose

Andrew C. Lodolo, PharmD, BCPS, BCCCP, FCCM


Nothing to disclose

Friedhelm Sandbrink, MD 


Nothing to disclose

Tanya J. Uritsky, PharmD, BCPP


Nothing to disclose

Dorothy Caputo, MA, BSN, RN - VP, Healthcare Continuing Education and Operations


Nothing to disclose

Bernadette Makar, MSN, APRN-BC, NP-C (planner/reviewer)


Nothing to disclose

Michele Bielarski, RN (planner/reviewer)



AKH Inc Staff and Planners


Nothing to disclose

PAINWeek Staff and Planners


Nothing to disclose

All of the relevant financial relationships listed for these individuals have been mitigated.


It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to with your information with "Opt Out" in the subject line.

Available Credit

  • 8.25 AANP
  • 8.25 AAPA Category I CME
  • 8.25 ACCME (All Other)
  • 8.25 ACCME (MD/DO Only)


Please login or register to take this course.

Required Hardware/software

1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
512 MB of RAM (1 GB recommended)

Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome

For HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)

1.83 GHz Intel Core Duo or faster processor
512 MB of RAM (1 GB recommended)
MAC OS X 10.12, 10.13 and 10.14

Mozilla Firefox, Apple Safari, Google Chrome

For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)